Opinion|Videos|January 13, 2025
Exploring Combination Therapy with Ibrutinib and Rituximab in cGVHD
Author(s)Sergio A. Giralt, MD
Sergio A. Giralt, MD, discusses how rituximab plays a key role in treating chronic graft-vs-host disease. It is often used in combination with ibrutinib to enhance therapeutic outcomes. He reviews the study design and efficacy and safety data from recent trials and discusses how these results will influence his clinical practice moving forward.
Advertisement
Video content above is prompted by the following:
- What is the role of rituximab in your clinical practice in patients with chronic graft-vs-host disease?
- Do you ever use rituximab in combination with ibrutinib?
- What were the study design and methods of this abstract?
- What were the key efficacy and safety results seen in this abstract?
- Will these results impact your clinical practice going forward?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss
2
Measles Cases Climb to 2000 in the US, Increasing Cases Year Over Year
3
Emerging Data Suggest Survodutide Targets Liver Fat More Rapidly Than Weight Loss: Lee Kaplan, MD, PhD
4
Survodutide Normalizes Liver Fat in 61% of Patients With MASLD in Phase 3 Trial: Lee Kaplan, MD, PhD
5